Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05046106 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MLC1501 Study Assessing Efficacy in STROke Recovery

Study acronym: MAEStro
StatusNot Yet Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Sep 2027 to Sep 2028
    • Start date: Jan 2024 to Jan 2025
    • Study completion date: Dec 2027 to Dec 2028
    v3
  2. Primary completion date: Sep 2025 to Sep 2027
    • Start date: Jan 2022 to Jan 2024
    • Study completion date: Dec 2025 to Dec 2027
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Moleac Pte Ltd.
2 trials monitored
See all monitored trials
Heart Disease
8,786 trials monitored
See 412 trials at risk
Stroke
3,531 trials monitored
See 153 trials at risk
This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a day, MLC1501 high-dose twice a day, or matching placebo for 24 weeks.
Trial Details
NCT Number NCT05046106
Lead Sponsor Moleac Pte Ltd.
Conditions
(from sponsor)		 Stroke, Stroke, Ischemic, Strokes Thrombotic, Stroke Sequelae, Stroke, Cardiovascular, Stroke, Embolic, Stroke, Cryptogenic
Related terms Embolic Stroke, Ischemic Stroke, Myocardial Infarction, Stroke, Thrombotic Stroke
Enrollment 540 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov